Unichem Laboratories Ltd

₹ 335 -9.24%
05 Dec - close price
About

Unichem Laboratories Ltd is involved in pharmaceuticals
in Generics, APIs and Contract Manufacturing (CMO) areas.[1]

Key Points

Therapeutic Areas
The company manufactures a wide range of APIs and pharmaceutical formulations as branded and simple generics. Its products cater to diverse range of therapeutic areas, such as cardiology, gastroenterology, diabetology, psychiatry, neurology and others. [1]

  • Market Cap 2,356 Cr.
  • Current Price 335
  • High / Low 467 / 226
  • Stock P/E
  • Book Value 367
  • Dividend Yield 1.20 %
  • ROCE -3.07 %
  • ROE -2.06 %
  • Face Value 2.00

Pros

  • Company is almost debt free.
  • Stock is trading at 0.91 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 10.4% over past five years.
  • Company has a low return on equity of -0.70% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2019 Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
225 231 216 241 311 311 261 201 217 248 277 245 266
261 257 227 249 267 280 233 230 227 265 264 256 297
Operating Profit -36 -26 -11 -8 44 32 28 -29 -10 -17 12 -11 -31
OPM % -16% -11% -5% -3% 14% 10% 11% -14% -5% -7% 5% -4% -12%
29 23 19 19 10 13 5 13 5 15 9 12 6
Interest 0 0 1 0 0 1 0 0 1 0 1 2 3
Depreciation 18 17 19 18 19 19 20 20 20 21 21 23 26
Profit before tax -25 -20 -12 -8 35 26 12 -36 -27 -24 -0 -23 -55
Tax % -0% -0% -0% -0% 14% -19% 93% 24% 19% -0% 6,289% -0% -38%
Net Profit -25 -20 -12 -8 30 30 1 -28 -21 -24 17 -23 -75
EPS in Rs -3.53 -2.89 -1.64 -1.07 4.31 4.32 0.12 -3.95 -3.04 -3.34 2.46 -3.31 -10.72
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
765 803 1,005 1,044 1,091 1,221 576 666 968 904 1,124 943 1,036
603 676 819 863 989 1,078 813 798 1,019 994 1,028 986 1,082
Operating Profit 161 127 186 181 102 142 -237 -132 -52 -89 95 -43 -46
OPM % 21% 16% 18% 17% 9% 12% -41% -20% -5% -10% 8% -5% -4%
8 9 14 84 20 19 366 2,737 94 98 47 42 42
Interest 2 3 2 2 2 2 2 3 1 1 1 2 6
Depreciation 27 28 35 43 38 35 39 45 62 71 76 83 92
Profit before tax 140 105 162 220 82 124 87 2,556 -20 -64 66 -87 -102
Tax % 23% 22% 20% 20% 21% 19% -19% -0% 144% 12% 18% 36%
Net Profit 108 82 130 177 64 100 104 2,557 9 -56 54 -55 -105
EPS in Rs 12.02 9.13 14.33 19.52 7.09 11.06 11.43 363.48 1.25 -8.00 7.68 -7.87 -14.91
Dividend Payout % 33% 33% 31% 41% 28% 18% 26% 1% 320% -50% 52% -51%
Compounded Sales Growth
10 Years: 2%
5 Years: 10%
3 Years: -1%
TTM: 5%
Compounded Profit Growth
10 Years: %
5 Years: 5%
3 Years: %
TTM: -466%
Stock Price CAGR
10 Years: 6%
5 Years: 2%
3 Years: 29%
1 Year: 38%
Return on Equity
10 Years: 16%
5 Years: 20%
3 Years: -1%
Last Year: -2%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
18 18 18 18 18 18 18 14 14 14 14 14 14
Reserves 660 712 795 888 929 1,009 1,112 2,748 2,718 2,633 2,683 2,658 2,570
31 48 6 1 0 8 1 0 -0 17 1 132 120
206 248 314 300 274 306 371 346 298 361 420 318 278
Total Liabilities 916 1,026 1,133 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,983
356 385 426 394 396 381 468 555 789 829 850 963 1,214
CWIP 63 111 129 86 119 233 247 236 90 331 568 494 211
Investments 100 106 140 120 153 111 89 979 1,042 668 520 390 129
397 424 437 607 555 617 698 1,338 1,109 1,197 1,181 1,275 1,429
Total Assets 916 1,026 1,133 1,207 1,222 1,342 1,503 3,108 3,030 3,025 3,119 3,122 2,983

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
81 129 180 87 88 117 141 -66 -251 -42 -33 -158
-53 -111 -127 35 -62 -87 -132 1,648 -323 -36 -73 104
-36 -15 -51 -98 -47 -39 -9 -930 -45 -21 -45 96
Net Cash Flow -9 3 3 24 -21 -9 -0 653 -619 -98 -150 42

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 88 84 77 74 69 79 188 127 125 130 117 147
Inventory Days 193 175 127 183 159 162 371 216 242 301 326 438
Days Payable 152 169 153 149 122 153 334 220 170 199 159 150
Cash Conversion Cycle 128 89 51 108 106 88 225 123 197 233 284 436
Working Capital Days 100 84 62 102 95 100 233 190 222 221 208 286
ROCE % 21% 14% 20% 19% 9% 13% -8% 132% -0% -2% 2% -3%

Shareholding Pattern

Numbers in percentages

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
50.62 50.74 50.93 50.93 50.93 50.93 50.93 50.93 50.93 50.93 50.93 50.94
1.89 1.76 1.61 1.59 1.55 1.50 1.54 1.53 1.45 1.47 1.50 1.71
9.37 9.46 9.23 9.18 9.08 8.94 9.09 9.09 9.30 9.59 9.53 8.70
38.12 38.04 38.23 38.29 38.44 38.62 38.43 38.44 38.32 38.01 38.04 38.67

* The XBRL reporting format changed from Sep'2022 onwards. The new format added details about banks and foreign portfolio investors. These were not available earlier.
The sudden increase in FII or DII might be because of these changes.

Please click on the line-items to see the names of individual entities.

Documents